Table Of Contents
- Chapter 1. Research Methodology and Scope
- Market Segmentation and Scope
- Regional Coverage
- Objectives
- Research Methodology
- Chapter 2. Executive Summary
- Market Landscape
- Market Size & Forecast
- Competitive Landscape
- Chapter 3. Brain Cancer Market: By Treatment Type Segment Market Trends, Size, and Future Outlook
- By Treatment Type Segment Market Size (US$), CAGR (%), and Forecast (2022-2030)
- By Treatment Type Segment Definitions, Technology Landscape
- By Treatment Type Segment Market Drivers
- Advances in surgical techniques
- Innovation in radiation therapy
- Emerging immunotherapies
- By Treatment Type Segment Market Restraints
- Challenges in drug delivery across blood-brain barrier
- Toxicities associated with chemo and radiation therapy
- Chapter 4. Brain Cancer Market: By Distribution Channel Segment Market Trends, Size, and Future Outlook
- By Distribution Channel Segment Market Size (US$), CAGR (%), and Forecast (2022-2030)
- By Distribution Channel Segment Definitions, Technology Landscape
- By Distribution Channel Segment Market Drivers
- Rising hospitalization for brain tumor treatment
- Increasing specialty clinics for cancer care
- Growth in cancer research centers
- By Distribution Channel Segment Market Restraints
- Limited healthcare access in low-income countries
- Chapter 5. Brain Cancer Market: Regional Market Trends, Size, and Future Outlook
- North America Market Size (US$), CAGR (%), and Forecast (2022-2030)
- North America Market Drivers
- High incidence of brain cancer
- Presence of leading companies and R&D infrastructure
- Favorable reimbursements
- North America Market Restraints
- Stringent regulatory requirements
- North America Market Restraints
- Chapter 6. Brain Cancer Market: Competitive Landscape
- Hoffmann-La Roche
-
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
-
- AbbVie
-
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
-
- Amgen
-
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
-
- Merck & Co.
-
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
-
- Bristol-Myers Squibb
-
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
-
- Novocure
-
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
-
- Varian Medical Systems
-
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
-
- Elekta
-
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
-
- Accuray
-
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
-
- Ion Beam Applications
-
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
-
- Mevion Medical Systems
-
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
-
- Hitachi
-
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
-
- Philips Healthcare
-
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
-
- GE Healthcare
-
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
-
- Siemens Healthineers
-
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
-
- Canon Medical Systems
-
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
-
- Nordion
-
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
-
- Isoray
-
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
-
- ViewRay
-
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
-
- Brainlab
-
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
-
- Research Methodology
- Primary Research
- Secondary Research
- Assumptions
- IDataAcumen Analysis
- Paid Databases
- Appendix
- About Us
Frequently Asked Questions
The current market size of the brain cancer industry is USD 2.9 billion in 2023.
Rising prevalence of brain tumors, Improving diagnosis and screening rates, Emergence of novel therapies like immunotherapy, targeted drugs, Rising healthcare expenditure and research funding, Increasing geriatric population, Advances in radiation therapy and surgical techniques
Low awareness in developing regions, High cost of therapies, Stringent regulations for drug approval, Failure of many clinical trials, Adverse effects of radiation and chemotherapy
Gliomas are the leading tumor type segment in the brain cancer market.
Hoffmann-La Roche, AbbVie, Amgen, Merck & Co., Bristol-Myers Squibb, Novocure, Varian Medical Systems, Elekta, Accuray, Ion Beam Applications, Brainlab.
The market is expected to grow at a CAGR of 7.8% from USD 2.9 billion in 2023 to USD 4.9 billion by 2030.
Rising prevalence and incidence rates, Improved diagnosis and screening tools, Emerging targeted therapies and immunotherapies, Rising healthcare spending and research funding, Advances in radiation therapy and surgical techniques, Growing geriatric population.